Strides Pharma Science Ltd reported a strong performance for the quarter ended June 30, 2025, with revenue from operations rising 6.2% YoY to ₹1119.7 crore. The company’s operational profit after tax (PAT) rose sharply by 80.6% year-on-year to ₹114 crore, while reported PAT stood at ₹105.6 crore.
EBITDA for the quarter was ₹218.1 crore, reflecting a 14.8% YoY growth, and the EBITDA margin expanded by 150 basis points to 19.5%. Gross margins improved significantly, reaching 60.3%, up 300 bps from the previous year, supported by better product mix and operational efficiencies.
On a quarter-on-quarter basis, revenue declined by 5.9% from ₹1190.4 crore in Q4 FY25. EPS for the quarter stood at ₹12.4.
Managing Director and Group CEO Badree Komandur stated:
“Our focused execution and tight cost management have helped us deliver a strong operating performance. We plan to invest more in R&D to support sustainable long-term growth.”
In the US market, revenue grew 7% YoY to $71 million (approx ₹591 crore), driven by base business and cost-optimized new launches. Strides now commercializes 70 products in the US, with a top-3 market ranking in 37 of them. The company reiterated its target of reaching $400 million (₹3,328 crore) in US revenues by FY27–28.
In other regulated markets, including Europe, revenue grew 9.2% YoY to ₹361.5 crore. In growth markets (including Africa and emerging countries), revenue was ₹140.2 crore, marking a 32.2% increase YoY. Meanwhile, access markets saw revenue decline by 72.9% YoY to ₹14.5 crore, due to lower donor-driven tenders.
The company also reported a net debt reduction of ₹264 crore, even after spending ₹291 crore in capital expenditure during the quarter. Return on capital employed (ROCE) stood at 15.1%, and Strides received a credit rating upgrade to ‘CARE A Positive’.
Looking forward, the company expects growth to continue across core markets and is ramping up its portfolio of differentiated products such as controlled substances and nasal sprays to support future expansion.